Literature DB >> 17054996

Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.

Yupei Zhao1, Songjie Shen, Junchao Guo, Herbert Chen, David Yu Greenblatt, Jörg Kleeff, Quan Liao, Ge Chen, Helmut Friess, Po Sing Leung.   

Abstract

BACKGROUND: Chemoresistance is an important clinical problem in pancreatic cancer. As the mitogen-activated protein kinases (MAPKs) have been found to be involved in the development of chemoresistance in a variety of cancer cell lines, the aim of the current study was to assess the role and mechanism of MAPK signaling in mediating chemoresistance in pancreatic cancer cells.
MATERIALS AND METHODS: The effects of pharmacological inhibition of MAPKs on resistance of pancreatic cancer cells to apoptosis induced by treatment with chemotherapeutic drugs were analyzed.
RESULTS: Compared with parental cells, the activity of extracellular signal-regulated kinase (ERK) was elevated in all of the three chemoresistant sublines at basal conditions. Inhibition of the ERK pathway by PD98059 sensitized cells to 5-fluorouracil (5-FU), whereas cells became more resistant to Adriamycin (ADM; Meiji Seika, Tokyo, Japan) and gemcitabine (GEM). 5-FU induced apoptosis primarily via a caspase-8-dependent pathway, and ADM and GEM via caspase-9. PD98059 enhanced the activity of caspase-8 and inhibited the activation of caspase-9. In addition, PD98059 regulated the level of phospho-Bcl-2.
CONCLUSIONS: These data suggest that although constitutive activation of the ERK pathway might be a marker of chemoresistance, the effects of this pathway on chemoresistance of pancreatic cancer cells are drug dependent. This study also provides evidence for a possible link between the ERK pathway and activation of the caspases and Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17054996     DOI: 10.1016/j.jss.2006.06.031

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  26 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

2.  Panorama from the oncolytic virotherapy summit.

Authors:  Jonathan G Pol; Monique Marguerie; Rozanne Arulanandam; John C Bell; Brian D Lichty
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

Review 3.  Long non-coding RNAs in cancer invasion and metastasis.

Authors:  Xiao-han Shen; Peng Qi; Xiang Du
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

Review 4.  Recent studies of 5-fluorouracil resistance in pancreatic cancer.

Authors:  Wei-Bin Wang; Yu Yang; Yu-Pei Zhao; Tai-Ping Zhang; Quan Liao; Hong Shu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

5.  An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.

Authors:  Sumit Arora; Arun Bhardwaj; Seema Singh; Sanjeev K Srivastava; Steven McClellan; Chaitanya S Nirodi; Gary A Piazza; William E Grizzle; Laurie B Owen; Ajay P Singh
Journal:  J Biol Chem       Date:  2013-06-05       Impact factor: 5.157

6.  CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.

Authors:  S Singh; S K Srivastava; A Bhardwaj; L B Owen; A P Singh
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

7.  Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

Authors:  Callum M Sloss; Fang Wang; Rong Liu; Lijun Xia; Michael Houston; David Ljungman; Michael A Palladino; James C Cusack
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

8.  A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Authors:  Jessica E Pritchard; Patrick M Dillon; Mark R Conaway; Corinne M Silva; Sarah J Parsons
Journal:  Oncology       Date:  2012-09-05       Impact factor: 2.935

Review 9.  Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.

Authors:  Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Drug Resist Updat       Date:  2008-04-28       Impact factor: 18.500

10.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.

Authors:  Martin Michaelis; Denise Klassert; Susanne Barth; Tatyana Suhan; Rainer Breitling; Bernd Mayer; Nora Hinsch; Hans W Doerr; Jaroslav Cinatl; Jindrich Cinatl
Journal:  Mol Cancer       Date:  2009-09-29       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.